Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.

The 90-day TFV ring was well-tolerated, acceptable and exceeded target cervical tissue concentrations through day 56, but declined thereafter. Additional studies are needed to characterize the higher release from TFV rings in some participants and the optimal duration of use.